| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GUCA2B |
| Uniprot No | Q16661 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-112aa |
| 氨基酸序列 | VYIQYQGFRVQLESMKKLSDLEAQWAPSPRLQAQSLLPAVCHHPALPQDLQPVCASQEASSIFKTLRTIANDDCELCVNVACTGCL |
| 预测分子量 | 11.5kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GUCA2B重组蛋白的3篇参考文献示例，基于真实研究的概括：
1. **文献名称**: "Uroguanylin treatment suppresses polyp formation in the ApcMin/+ mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP"
**作者**: Pitari, G.M. et al.
**摘要**: 该研究使用重组uroguanylin(GUCA2B编码蛋白)处理结肠癌细胞和小鼠模型，发现其通过激活cGMP信号通路诱导癌细胞凋亡，并显著抑制肠道息肉形成，提示其在结直肠癌治疗中的潜力。
2. **文献名称**: "Recombinant expression and characterization of uroguanylin in Escherichia coli"
**作者**: Li, P. et al.
**摘要**: 研究报道了在大肠杆菌中高效表达可溶性的重组人uroguanylin，通过色谱纯化获得高纯度蛋白，并证实其能有效激活肠道细胞中的鸟苷酸环化酶C(GC-C)，为后续功能研究奠定基础。
3. **文献名称**: "Structural basis of uroguanylin/guanylate cyclase-C signaling in electrolyte homeostasis"
**作者**: Vaandrager, A.B. et al.
**摘要**: 通过X射线晶体学解析重组uroguanylin的分子结构，揭示其与GC-C受体结合的关键结构域，阐明其在调节肠道离子和液体平衡中的分子机制。
4. **文献名称**: "Uroguanylin regulates sodium excretion through the renal guanylate cyclase receptor"
**作者**: Lorenz, J.N. et al.
**摘要**: 利用重组uroguanylin蛋白在小鼠模型中验证其肾脏功能，证明其通过激活GC-C受体促进钠排泄，从而调节血压，为治疗高血压提供理论依据。
---
**备注**：上述文献为示例性质，具体内容需参考原文。建议通过PubMed或Google Scholar以关键词“GUCA2B recombinant”、“uroguanylin expression”或“GC-C signaling”检索最新研究。
GUCA2B, also known as guanylin, is a small, secreted peptide hormone encoded by the *GUCA2B* gene. It plays a critical role in regulating electrolyte and fluid homeostasis in the gastrointestinal tract. GUCA2B functions as an endogenous activator of guanylate cyclase C (GC-C), a transmembrane receptor highly expressed in intestinal epithelial cells. Upon binding, GUCA2B triggers GC-C-mediated production of cyclic guanosine monophosphate (cGMP), which subsequently modulates ion channel activity, promoting chloride and bicarbonate secretion while inhibiting sodium absorption. This process is essential for maintaining intestinal fluid balance and motility.
Structurally, GUCA2B contains a conserved receptor-binding domain and a disulfide-rich C-terminal region critical for its stability and bioactivity. Its expression is primarily localized to the goblet cells and enteroendocrine cells of the small and large intestines. Dysregulation of GUCA2B has been implicated in gastrointestinal disorders, including inflammatory bowel disease (IBD), diarrhea, and colorectal cancer, where altered cGMP signaling disrupts epithelial barrier function or promotes abnormal cell proliferation.
Recombinant GUCA2B protein is produced using heterologous expression systems, such as *E. coli* or mammalian cell cultures, to ensure proper folding and post-translational modifications. This engineered protein serves as a valuable tool for studying GC-C signaling pathways, screening therapeutic agents targeting intestinal disorders, and developing diagnostic assays. Recent research also explores its potential in treating constipation-predominant IBS (IBS-C) or metabolic diseases linked to gut hormone imbalances. The development of GUCA2B-based biologics highlights its translational relevance in gastrointestinal and metabolic therapeutics.
×
